Ribonucleic Acid (RNA) Markers Market, by Type (Prestained Markers, Unstained Markers and Specialty Markers), by Application (Nucleic Acid Applications and Proteomics Applications), by End User (Research Centers, Pharmaceutical and Biotechnology Companies and Others (Academic Institutes, Forensic Laboratory and Others)) by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Mar 2023

Code : CMI5584

Pages :195

Formats :

Excel and PDF

Industry : Biotechnology

Market Challenges And Opportunities

Global Ribonucleic Acid (RNA) Markers Market- Driver

Facility expansion by the market players to drive the growth of the Ribonucleic Acid (RNA) Markers Market

Market players are indulged in facility expansion, which is expected to increase the production of nucleic acid products including RNA markers, which is expected to drive the growth of the Ribonucleic Acid (RNA) markers market over the forecast period. For instance, in November 2022, Celerion, a clinical research organization (CRO), expanded its molecular and cellular capabilities to Good Laboratory Practice/Good Clinical Practice (GLP/GCP) standards, in order to support the development of new modality therapies, such as cell and gene therapies. The expanded service offering is available in both of the company’s locations, i.e., Lincoln and Zürich bioanalytical laboratories and this includes ELISpot analysis, flow cytometry, and qPCR

Global Ribonucleic Acid (RNA) Markers Market: Key Developments

On July 5, 2022, Eurofins Discovery, a U.S based drug discovery company, acquired contract research organization, DiscoveryBioMed, a life sciences and biotechnology company. This acquisition contributed to Eurofins Discovery's aim of offering array of drug discovery services and products.

Global Ribonucleic Acid (RNA) Markers Market: Restraint

Stringent Guidelines to handle RNA Sample

Stringent laboratory guidelines to handle RNA samples is expected to hamper the growth of the global ribonucleic acid (RNA) markers market, over the forecast period. For instance, according to the National Center for Biotechnology Information (NCBI): 2021, the following are some of the stringent guidelines mentioned, which if not followed may lead to the degradation of the RNA molecules:

Wear clean gloves and a lab coat. Remove gloves before touching items usually touched with bare hands, e.g., computer. Change gloves frequently.
The work area should be clean with RNAseZAP before initiating the procedures
The micropipettes should be used with RNAse free barrier pipettes tips
All solutions should be made with RNase-free water and used only for RNA work

During the COVID-19 pandemic there was increase in the growth of the global ribonucleic acid (RNA) markers market owning to launch of RNA extraction kits during COVID-19 pandemic. In the year 2021, Porvair Sciences, engaged in the development and manufacture of raw materials, launched new kits for rapid extraction of total RNA from a wide range of biological samples. These proprietary kits enable extraction of up to 1000 µg (microgram) of application-ready pure RNA in as little as 10 minutes. Extraction of RNA is the first step to identify any viral contamination and all the research after the extraction of RNA from the samples.

Moreover, due to increasing research and development activities for the production of COVID-19 vaccines, market players were collaborating by supplying raw materials required for the production of vaccines, which also included RNA markers. For instance, in 2020, Sanofi and BioNTech entered into an agreement under which Sanofi supported the manufacturing and supply of BioNTech’s COVID-19 mRNA vaccine, which was being co-developed with Pfizer Inc. Under this agreement, Sanofi provided BioNTech the access to its established infrastructure and expertise to produce over 125 million doses of COVID-19 mRNA vaccine in Europe.